Depo-Medrol prescribing information |
|
 |
|
Depo-Medrol notes:
Depo-Medrol is an anti-inflammatory glucocorticoid prescribed for intramuscular, intrasynovial, soft tissue or intralesional injection.
Intramuscular administration of depo-medrol is recommended for endocrine disorders, rheumatic disorders, post-traumatic osteoarthritis, collagen diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders and neoplastic diseases.
Intrasynovial or Soft Tissue administration of depo-medrol is indicated as adjunctive therapy for short-term administration in synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis and post-traumatic osteoarthritis.
Depo-Medrol is suggested for intralesional use in keloids, discoid lupus erythematosus, necrobiosis lipoidica diabeticorum and alopecia areata.
Contraindication for intrathecal administration is observed when Depo-Medrol is administered in the form of aqueous suspension. It is also contraindicated resulting in fungal infections and patients who are hypersensitive to depo-medrol should avoid taking it.
Depo-Medrol is not suitable for multi-dose use. In order to avoid and minimize the occurrence of dermal and subdermal atrophy, recommended doses in injections should never be exceeded. Long term use of corticosteroids may result in posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves. The administration of depo-medrol poses adverse effects during pregnancy and on nursing mothers.
Mutual inhibition of metabolism and convulsions may result in when cyclosporin is used along with methylprednisolone. Drugs such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone whereas drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Hence the dosage of methylprednisolone should be titrated to avoid further complications.
Adverse reactions resulting due to the administration of depo-medrol are fluid and electrolyte disturbances, musculoskeletal, gastrointestinal, dermatologic, neurological, endocrinal, ophthalmic and metabolic disorders.
Depo-Medrol sterile aqueous suspension is available as single-dose vials with the strengths 40 mg per ml 80 mg per ml. It should be stored at controlled room temperature 20° to 25°C.
How is Depo-Medrol Supplied
Depo-Medrol Sterile Aqueous Suspension is available as single-dose vials in the following strengths and package sizes:
40 mg per mL 80 mg per mL
1 mL vials NDC 0009-3073-01 1 mL vials NDC 0009-3475-01
25 × 1 mL vials NDC 0009-3073-03 25 × 1 mL vials NDC 0009-3475-03
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
Items: depo medrol injection, depo medrol mg, depo medrol for, depo medrol side effects.
No To Hattatsu. 2008 Jul;40(4):324-7.
Kuki I et all.
Successful steroid pulse therapy for acute unilateral oculomotor nerve palsy associated with norovirus infection
The study was done in a 4 years old boy who developed acute unilateral oculomotor nerve palsy following Norovirus infection. Scientists performed three course of steroid pulse therapy using methylprednisolone combined with vitamin B6 and autonomic dysfunction began to improve in several days subsequently extraocular movements resolved completely in one month.
Arq Neuropsiquiatr. 2008 Jun;66(2B):350-3.
Methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis
Approved treatment for the primary progressive multiple sclerosis (PPMS) is very less. In this study by using methyl prednisolone IV in 11 patients, good improvement was recorded.
J Infect. 2008 Jul 23.
Tamura A et all.
Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia
The following study is to determine the efficacy of methyl prednisolone pulse therapy for children with mycoplasma pneumoniae pneumonia (MP). After treatment with this resulted that the effect of 3-day methyl prednisolone therapy on MP in children is significant.
Turk J Pediatr. 2008 Mar-Apr;50(2):171-5.
Unal S at all.
The rapid correction of hypercalcemia at presentation of acute lymphoblastic leukemia using high-dose methylprednisolone.
Hyperglycemia is a complication of neoplastic disorders. In treatment with chemotherapy protocol including vincristine, daunomycin and high dose methylprednisolone, and methylprednisolone corrected the severe hyperglycemia.
Muscle Nerve. 2008 Jul 31;38(3):1161-1172.
Sassoon CS et all.
Effects of methylprednisolone on diaphragm muscle function
The study was done for explaining the effects of acute high dose corticosteroids on the diaphragm muscles. For this rabbits and used for explanation with 3 group administration including control and resulted that very high dose methylprednisolone can produce rapid reduction in diaphragmatic function, where as pulse dose methyl prednisolone produces modest functional loss.
Curr Drug Saf. 2007 May;2(2):113-6.
Brill S et all.
Epidural steroid injections do not induce weight gain.
In this study scientist evaluated the effect of three consecutive epidural steroid injections with 40mg methyl prednisolone for identifying whether there is weight gain and resulted that neuraxial steroid administration doesn’t induce weight gain.
Arch Dis Child. 2008 Aug 13.
Chartapisak W et all.
Prevention and treatment of renal disease in Henoch-Schonlein Purpura
In this study ten trials involving 1230 children aged less than 18 years are treated and determined the benefits and harms of therapies used to prevent or treat renal involvement in Henoch-Schonlein Purpura. Study reached the conclusion that data from randomized trial for any intervention used in children with Henoch-Schönlein Purpura are very sparse except for short-term prednisone.
Int J Hematol. 2008 Aug 19.
Shima T et all.
Treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone
Depo-Medrol review article...
|
My Basket
